Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 May;61(5):1168–1175. doi: 10.1172/JCI109032

The Effects of Ristocetin and von Willebrand Factor on Platelet Electrophoretic Mobility

Barry S Coller 1
PMCID: PMC372637  PMID: 307006

Abstract

Ristocetin will induce the agglutination of platelets in the presence of von Willebrand factor. In previous studies, an electrostatic mechanism was proposed for this phenomenon wherein first the platelet's surface charge is reduced by the binding of ristocetin and then the von Willebrand factor acts as a bridge between platelets. To test this hypothesis, the effects of ristocetin and von Willebrand factor, singly and together, on the electrophoretic mobility of normal, trypsinized, and Bernard-Soulier platelets was measured. Ristocetin alone, at concentrations of 0.5 mg/ml or more, produced a statistically significant reduction in the electrophoretic mobility of fresh or fixed platelets. Control experiments showed that the reduction was not due to changes in the ionic milieu of the solution. Therefore, the decrease in platelet mobility is evidence for binding of ristocetin to the platelet surface. Bernard-Soulier and trypsinized platelets also had reductions in mobility with ristocetin, suggesting that ristocetin binds to the platelet at sites other than the binding site for von Willebrand factor. The presence of plasma from a patient with von Willebrand's disease did not alter the reduction in mobility of normal platelets by ristocetin. However, the reduction was markedly enhanced in the presence of normal plasma. This enhancement did not occur with Bernard-Soulier platelets and was inhibited by anti-Factor VIII/von Willebrand factor antiserum or trypsinization of the platelets. Thus, the enhanced reduction appears to be associated with the binding of von Willebrand factor to the platelet surface. These studies indicate that platelets undergo two changes with ristocetin and von Willebrand factor, both of which facilitate agglutination: reduction in net surface charge and binding of von Willebrand factor, a large molecule which can serve as a bridge between platelets. In parallel studies, bovine von Willebrand factor, without ristocetin, agglutinated and reduced the electrophoretic mobility of normal but not Bernard-Soulier or trypsinized platelets; this indicates a similar mechanism of agglutination.

Full text

PDF
1168

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain J. P., Cooper H. A., Wagner R. H., Brinkhous K. M. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med. 1975 Feb;85(2):318–328. [PubMed] [Google Scholar]
  2. BANGHAM A. D., HEARD D. H., FLEMANS R., SEAMAN G. V. An apparatus for microelectrophoresis of small particles. Nature. 1958 Sep 6;182(4636):642–644. doi: 10.1038/182642a0. [DOI] [PubMed] [Google Scholar]
  3. Baugh R. F., Brown J. E., Hougie C. Preparation and platelet aggregating activity of 125I-labeled ristocetin. Anal Biochem. 1977 Mar;78(1):39–46. doi: 10.1016/0003-2697(77)90005-7. [DOI] [PubMed] [Google Scholar]
  4. Bithell T. C., Parekh S. J., Strong R. R. Platelet-function studies in the Bernard-Soulier syndrome. Ann N Y Acad Sci. 1972 Oct 27;201:145–160. doi: 10.1111/j.1749-6632.1972.tb16296.x. [DOI] [PubMed] [Google Scholar]
  5. Caen J. P., Nurden A. T., Jeanneau C., Michel H., Tobelem G., Levy-Toledano S., Sultan Y., Valensi F., Bernard J. Bernard-Soulier syndrome: a new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med. 1976 Apr;87(4):586–596. [PubMed] [Google Scholar]
  6. Coller B. S., Franza B. R., Jr, Gralnick H. R. The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH. Blood. 1976 May;47(5):841–854. [PubMed] [Google Scholar]
  7. Coller B. S., Gralnick H. R. Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest. 1977 Aug;60(2):302–312. doi: 10.1172/JCI108778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coller B. S., Hirschman R. J., Gralnick H. R. Studies on the Factor VIII/von Willebrand factor antigen on human platelets. Thromb Res. 1975 Jun;6(6):469–480. doi: 10.1016/0049-3848(75)90059-6. [DOI] [PubMed] [Google Scholar]
  9. Floyd M., Burns W., Green D. On the interaction between ristocetin and the ristocetin cofactor (RCOF). Thromb Res. 1977 Jun;10(6):841–850. doi: 10.1016/0049-3848(77)90141-4. [DOI] [PubMed] [Google Scholar]
  10. Forbes C. D., Prentice C. R. Aggregation of human platelets by purified porcine and bovine antihaemophilic factor. Nat New Biol. 1973 Jan 31;241(109):149–150. doi: 10.1038/newbio241149a0. [DOI] [PubMed] [Google Scholar]
  11. Green D., Potter E. V. Platelet-bound ristocetin aggregation factor in normal subjects and patients with von Willebrand's disease. J Lab Clin Med. 1976 Jun;87(6):976–986. [PubMed] [Google Scholar]
  12. Gröttum K. A. Platelet surface charge and aggregation. Effects of polyelectrolytes. Thromb Diath Haemorrh. 1969 Jun 15;21(3):450–462. [PubMed] [Google Scholar]
  13. Gröttum K. A., Solum N. O. Congenital thrombocytopenia with giant platelets: a defect in the platelet membrane. Br J Haematol. 1969 Mar;16(3):277–290. doi: 10.1111/j.1365-2141.1969.tb00402.x. [DOI] [PubMed] [Google Scholar]
  14. Howard M. A., Firkin B. G. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971 Oct 31;26(2):362–369. [PubMed] [Google Scholar]
  15. Howard M. A. Inhibition and reversal of ristocetin - induced platelet aggregation. Thromb Res. 1975 Jun;6(6):489–499. doi: 10.1016/0049-3848(75)90061-4. [DOI] [PubMed] [Google Scholar]
  16. Jaffe E. A., Hoyer L. W., Nachman R. L. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A. 1974 May;71(5):1906–1909. doi: 10.1073/pnas.71.5.1906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jenkins C. S., Phillips D. R., Clemetson K. J., Meyer D., Larrieu M. J., Lüscher E. F. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest. 1976 Jan;57(1):112–124. doi: 10.1172/JCI108251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kattlove H. E., Gomez M. H. Studies on the mechanism of ristocetin-induced platelet aggregation. Blood. 1975 Jan;45(1):91–96. [PubMed] [Google Scholar]
  19. Kirby E. P. Evans blue: a specific inhibitor of factor VIII-induced platelet agglutination. Thromb Diath Haemorrh. 1975 Dec 15;34(3):770–779. [PubMed] [Google Scholar]
  20. Kirby E. P., Mills D. C. The interaction of bovine factor VIII with human platelets. J Clin Invest. 1975 Aug;56(2):491–502. doi: 10.1172/JCI108116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McPherson J., Zucker M. B. Platelet retention in glass bead columns: adhesion to glass and subsequent platelet-platelet interactions. Blood. 1976 Jan;47(1):55–67. [PubMed] [Google Scholar]
  22. Meyer D., Jenkins C. S., Dreyfus M. D., Fressinaud E., Larrieu M. J. Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Br J Haematol. 1974 Dec;28(4):579–599. doi: 10.1111/j.1365-2141.1974.tb06676.x. [DOI] [PubMed] [Google Scholar]
  23. Nieto M., Perkins H. R. The specificity of combination between ristocetins and peptides related to bacterial cell wall mucopeptide precursors. Biochem J. 1971 Oct;124(5):845–852. doi: 10.1042/bj1240845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Perkins H. R., Nieto M. The chemical basis for the action of the vancomycin group of antibiotics. Ann N Y Acad Sci. 1974 May 10;235(0):348–363. doi: 10.1111/j.1749-6632.1974.tb43276.x. [DOI] [PubMed] [Google Scholar]
  25. Seaman G. V., Vassar P. S. Changes in the electrokinetic properties of platelets during their aggregation. Arch Biochem Biophys. 1966 Oct;117(1):10–17. doi: 10.1016/0003-9861(66)90119-6. [DOI] [PubMed] [Google Scholar]
  26. Walsh P. N., Mills D. C., Pareti F. I., Stewart G. J., Macfarlane D. E., Johnson M. M., Egan J. J. Hereditary giant platelet syndrome. Absence of collagen-induced coagulant activity and deficiency of factor-XI binding to platelets. Br J Haematol. 1975 Apr;29(4):639–655. doi: 10.1111/j.1365-2141.1975.tb02750.x. [DOI] [PubMed] [Google Scholar]
  27. Weiss H. J. Platelet physiology and abnormalities of platelet function (second of two parts). N Engl J Med. 1975 Sep 18;293(12):580–588. doi: 10.1056/NEJM197509182931204. [DOI] [PubMed] [Google Scholar]
  28. Weiss H. J., Rogers J., Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest. 1973 Nov;52(11):2697–2707. doi: 10.1172/JCI107464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Weiss H. J., Tschopp T. B., Baumgartner H. R., Sussman I. I., Johnson M. M., Egan J. J. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med. 1974 Dec;57(6):920–925. doi: 10.1016/0002-9343(74)90170-3. [DOI] [PubMed] [Google Scholar]
  30. ZUCKER M. B., LEVINE R. U. MICROELECTROPHORESIS OF WASHED AND UNWASHED HUMAN BLOOD PLATELETS, WITH ADDITIONAL STUDIES OF PLATELETS FROM PATIENTS WITH VON WILLEBRAND'S DISEASE AND THROMBASTHENIA. Thromb Diath Haemorrh. 1963 Nov 1;10:1–8. [PubMed] [Google Scholar]
  31. Zucker M. B., Kim S. J., McPherson J., Grant R. A. Binding of factor VIII to platelets in the presence of ristocetin. Br J Haematol. 1977 Apr;35(4):535–549. doi: 10.1111/j.1365-2141.1977.tb00619.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES